Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus
about
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitroEfficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistanceCloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutationsPharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis.Antimicrobial susceptibility of coagulase-negative staphylococci.Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteriaIn vivo selection during pefloxacin therapy of a mutant of Staphylococcus aureus with two mechanisms of fluoroquinolone resistance.Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection modelEvolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.Examination of methicillin-resistant and methicillin-susceptible Staphylococcus aureus mutants with low-level fluoroquinolone resistanceTOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureusAnalysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.Cloning and sequencing of a novel gene (recG) that affects the quinolone susceptibility of Staphylococcus aureus.Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus.Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.Psammaplin A, a natural bromotyrosine derivative from a sponge, possesses the antibacterial activity against methicillin-resistant Staphylococcus aureus and the DNA gyrase-inhibitory activity.In vitro stepwise selection of resistance to quinolones, beta-lactams and amikacin in nosocomial gram-negative bacilli.
P2860
Q24673222-D5B82D9E-B26B-49E0-A5C3-0F703C61C101Q28361569-09675916-A5D7-4A98-99B5-AF801B3BDA54Q28369291-AED9CC56-0526-4ADF-A4D0-4FDA199270A7Q33555316-14B5A5A3-A6C8-48C9-AFE1-0EE91532BD37Q33695982-4E3343B2-3E49-431E-9677-506A3FD6A9C1Q33758823-A25C9764-51BA-43D0-831F-78DCA800C63FQ33760227-B0459301-5E8D-4392-920F-3027C863C8B7Q33983660-F9426B3C-7029-4B84-B211-D003CD677B5AQ35126142-805C49CF-3B52-4AC1-8B44-A70BF2E0C4AFQ35138781-C5DE314D-85CD-43EC-931A-0C43BAB39ED9Q35574888-9B6EBC91-97B6-4C8A-874A-476F33A7E38FQ35820858-DC2F082F-FA7B-4FA0-B978-679210AD5B35Q35822889-77F57F2D-F55E-42D5-AB31-61BD1A454B86Q37624733-E88DC837-89C9-4902-A48B-DC5C526E658BQ39558211-5228BE92-C9A2-4BDC-A4FD-F9396291878FQ39559188-36618A4C-6E37-4D8C-AEDC-3AA95288CA24Q39559760-86FBC22B-59BF-4F28-BEF6-278C7845E5F5Q39779720-282BD1BE-DCF5-49E2-AB05-4F32F0454432Q39780047-9A7B4454-ECAD-40C9-A7B9-E4F2D43AAAE9Q39782024-4CC75D93-A4F0-4B18-AC32-9310E4A2AE0CQ39784742-07DC2D27-6BF5-491B-91FC-B7C112D52D1BQ40286293-2C43C5EE-C533-4B70-A2BA-8E2B0B81F5C5Q40833065-86050E32-93D9-4FBF-A320-5863B65FF43FQ42784827-38A5A2AD-9DE6-434E-A568-D81A71F6FA70Q54103069-31B0BCA1-FF27-4420-9DB9-68EA0DFF0A57Q54221210-6413E8EC-33EC-47CD-B8C3-F63C9E79169E
P2860
Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Sequential acquisition of norf ...... ceptible Staphylococcus aureus
@ast
Sequential acquisition of norf ...... ceptible Staphylococcus aureus
@en
type
label
Sequential acquisition of norf ...... ceptible Staphylococcus aureus
@ast
Sequential acquisition of norf ...... ceptible Staphylococcus aureus
@en
prefLabel
Sequential acquisition of norf ...... ceptible Staphylococcus aureus
@ast
Sequential acquisition of norf ...... ceptible Staphylococcus aureus
@en
P2093
P2860
P356
P1476
Sequential acquisition of norf ...... ceptible Staphylococcus aureus
@en
P2093
P2860
P304
P356
10.1128/AAC.37.11.2278
P407
P577
1993-11-01T00:00:00Z